Tanja Meier

Q: What is Tanja Meier email address?

Email Tanja Meier at tanja.meier_@gmx.de and tanja.meier@heumann.de. This email is the most updated Tanja Meier's email found in 2026.

Q: How to contact Tanja Meier?

To contact Tanja Meier send an email to tanja.meier_@gmx.de or tanja.meier@heumann.de. (updated on March 07, 2025)

Pharmacovigilance Manager at VigiPRO® GmbH | Vohenstrauß, Bavaria, Germany

About Tanja Meier

Tanja Meier currently serves as the Pharmacovigilance Manager at VigiPRO® GmbH, where she plays a pivotal role in overseeing the company’s pharmacovigilance activities within Switzerland. With over 15 years of extensive experience in the pharmaceuticals industry, Tanja brings a deep expertise in PV oversight, regulatory intelligence, and safety data management. Her responsibilities include managing and updating Standard Operating Procedures (SOPs), ensuring compliance with local and international PV regulations, and maintaining the Pharmacovigilance System Master File (PSMF). She is also the designated Pharmacovigilance Responsible Person (QPPV) for Switzerland, providing strategic oversight and ensuring the safety of marketed products through rigorous signal detection, risk assessment, and adverse event reporting.

Tanja’s expertise extends to case processing, literature review, and the development of risk assessment reports, which are critical for proactive safety monitoring and regulatory submissions. Her proficiency in E2B messaging standards facilitates efficient adverse event reporting and data exchange with health authorities. At VigiPRO® GmbH, she is instrumental in managing complex PV projects, including clinical trial safety monitoring and post-marketing surveillance, with a focus on oncology and life sciences sectors. Her strong background in SOP writing, CAPA processes, and regulatory intelligence ensures that the company remains compliant with evolving global pharmacovigilance requirements. Tanja’s comprehensive skill set and strategic approach to PV management make her a valuable asset in safeguarding patient safety and supporting the company’s commitment to high-quality pharmaceutical safety practices.

Tanja Meier Work